Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The brokerage presently has a $127.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 12.77% from the stock’s current price.
According to Zacks, “Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis is likely to boost sales further. The prospects of ALXN1210 looks good too and a tentative approval will boost the top-line. Alexion is looking to diversify its portfolio and reduce its dependence on its blockbuster drug Soliris. The recently announced Wilson deal will strengthen Alexion’s rare disease pipeline with a late-stage candidate, WTX101 which is currently in phase III for the treatment of Wilson disease, a rare genetic disorder. Earlier, Alexion has de-prioritized a few clinical programs and terminated partnerships with Moderna Therapeutics among others. Shares of the company have performed better than the industry in the last three months. However, the company relies heavily on Soliris for growth and sales of the same will be impacted by ramp-up of ALXN1210 trials. Pricing will also hit sales.”
ALXN has been the topic of a number of other research reports. BidaskClub raised Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th. Morgan Stanley increased their price target on Alexion Pharmaceuticals from $148.00 to $151.00 and gave the stock an “overweight” rating in a research note on Friday, February 9th. Credit Suisse Group reissued an “outperform” rating and set a $147.00 price target on shares of Alexion Pharmaceuticals in a research note on Thursday, January 18th. Nomura increased their price target on Alexion Pharmaceuticals to $165.00 and gave the stock a “buy” rating in a research note on Thursday, April 12th. Finally, Raymond James reissued an “outperform” rating and set a $130.00 price target (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have given a buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $155.18.
ALXN stock traded down $0.34 on Thursday, reaching $112.62. The company had a trading volume of 222,535 shares, compared to its average volume of 2,122,822. Alexion Pharmaceuticals has a 1 year low of $96.18 and a 1 year high of $149.34. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10. The firm has a market cap of $25,188.75, a P/E ratio of 21.84, a PEG ratio of 1.01 and a beta of 1.13.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The firm had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. During the same quarter in the prior year, the company earned $1.26 EPS. Alexion Pharmaceuticals’s revenue was up 9.5% on a year-over-year basis. research analysts predict that Alexion Pharmaceuticals will post 6.12 earnings per share for the current year.
In related news, EVP John B. Moriarty sold 1,261 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $147,864.86. Following the completion of the sale, the executive vice president now directly owns 20,210 shares in the company, valued at approximately $2,369,824.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Heidi L. Wagner sold 655 shares of the stock in a transaction on Monday, February 5th. The shares were sold at an average price of $117.26, for a total value of $76,805.30. Following the completion of the sale, the senior vice president now owns 32,635 shares of the company’s stock, valued at $3,826,780.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,700 shares of company stock valued at $3,345,708. 4.35% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ALXN. Delpha Capital Management LLC acquired a new stake in Alexion Pharmaceuticals in the 4th quarter valued at $102,000. CNB Bank acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $150,000. Lourd Capital LLC acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $221,000. CIBC World Markets Inc. acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $263,000. Finally, Bailard Inc. acquired a new stake in shares of Alexion Pharmaceuticals during the fourth quarter valued at about $263,000. Hedge funds and other institutional investors own 95.09% of the company’s stock.
WARNING: “Alexion Pharmaceuticals (ALXN) Upgraded to Buy at Zacks Investment Research” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/19/alexion-pharmaceuticals-alxn-upgraded-to-buy-at-zacks-investment-research.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.